ProQR Therapeutics N.V.

NasdaqCM:PRQR Stock Report

Mkt Cap: US$138.8m

ProQR Therapeutics Management

Management criteria checks 2/4

ProQR Therapeutics’s CEO is Daniel de Boer, appointed in Feb 2012, he has a tenure of 11.3yrs. His total yearly compensation is €2.5m, comprised of 20.5% salary and 79.5% bonuses, including company stock and options. He directly owns 0.9% of the company’s shares, worth €1.2m. The average tenure of the management team and the board of directors is 3.3yrs and 5.1yrs respectively.

Key information

Daniel de Boer

Chief executive officer

€2.5m

Total compensation

CEO salary percentage20.5%
CEO tenure11.3yrs
CEO ownership0.9%
Management average tenure3.3yrs
Board average tenure5.1yrs

Recent management updates

Recent updates

Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

Mar 17
Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt

ProQR says EU regulator seeks additional trial for lead candidate

Aug 11

Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Nov 10
Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money

Investment Case On ProQR Therapeutics Gets More Enticing

Oct 01

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Aug 04
ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data

Jun 20

It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

May 13
It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year

ProQR Therapeutics offers a de-risked opportunity: Stifel

May 03

If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Mar 08
If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%

Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

Feb 01
Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?

ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder

Jan 07

ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

Dec 28
ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?

A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

Dec 01
A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns

ProQR reports Q3 results

Nov 16

CEO Compensation Analysis

How has Daniel de Boer's remuneration changed compared to ProQR Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Mar 31 2023n/an/a

-€60m

Dec 31 2022€2m€504k

-€65m

Sep 30 2022n/an/a

-€72m

Jun 30 2022n/an/a

-€62m

Mar 31 2022n/an/a

-€63m

Dec 31 2021€2m€449k

-€62m

Sep 30 2021n/an/a

-€57m

Jun 30 2021n/an/a

-€55m

Mar 31 2021n/an/a

-€43m

Dec 31 2020€3m€449k

-€47m

Sep 30 2020n/an/a

-€52m

Jun 30 2020n/an/a

-€51m

Mar 31 2020n/an/a

-€58m

Dec 31 2019€2m€449k

-€56m

Sep 30 2019n/an/a

-€51m

Jun 30 2019n/an/a

-€45m

Mar 31 2019n/an/a

-€40m

Dec 31 2018€1m€445k

-€37m

Sep 30 2018n/an/a

-€35m

Jun 30 2018n/an/a

-€40m

Mar 31 2018n/an/a

-€44m

Dec 31 2017€1m€353k

-€44m

Sep 30 2017n/an/a

-€41m

Jun 30 2017n/an/a

-€41m

Mar 31 2017n/an/a

-€39m

Dec 31 2016€827k€429k

-€39m

Compensation vs Market: Daniel's total compensation ($USD2.64M) is above average for companies of similar size in the US market ($USD754.43K).

Compensation vs Earnings: Daniel's compensation has increased whilst the company is unprofitable.


CEO

Daniel de Boer (39 yo)

11.3yrs

Tenure

€2,464,000

Compensation

Mr. Daniel Anton de Boer has been the Chief Executive Officer and Member of Management Board at ProQR Therapeutics N.V. since February 21, 2012. He serves as Member of Strategic Advisory Board at Hybridize...


Leadership Team

NamePositionTenureCompensationOwnership
Domenico Valerio
Founder & Independent Chairman of Supervisory Boardno data€178.00k0.52%
€ 722.6k
Daniel de Boer
Founder11.3yrs€2.46m0.87%
€ 1.2m
Rene Beukema
Chief Corporate Development Officerless than a year€463.00k0.57%
€ 790.1k
Gerard Platenburg
Co-Founder & Chief Scientific Officer11.3yrs€34.00kno data
Jurriaan Dekkers
Chief Financial Officerless than a yearno datano data
Sheila Sponselee
VP & Head of People and Operations3.3yrsno datano data
Sarah Kiely
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Sandra van der Kolk
Junior Financial Controllerno datano datano data

3.3yrs

Average Tenure

52yo

Average Age

Experienced Management: PRQR's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Domenico Valerio
Founder & Independent Chairman of Supervisory Board9.3yrs€178.00k0.52%
€ 722.6k
Antoine Papiernik
Independent Member of Supervisory Board9.3yrsno datano data
Arthur Levin
Member of Scientific Advisory Boardno datano datano data
Alison Lawton
Independent Member of Supervisory Board8.7yrs€156.00k0%
€ 0
Phillip Zamore
Member of Scientific Advisory Board5.9yrsno datano data
Theresa Heggie
Supervisory Board Memberno data€106.00kno data
James Shannon
Independent Member of Supervisory Board & Chairman of Scientific Advisory Board6.9yrs€163.00k0.076%
€ 105.7k
Bart Filius
Independent Supervisory Board Member4yrs€153.00k0%
€ 0
Martin Maier
Member of Scientific Advisory Board2.8yrsno datano data
Peter Beal
Member Scientific Advisory Board5.1yrsno datano data
Yi-Tao Yu
Member of Scientific Advisory Board5yrsno datano data
Begona Carreno
Supervisory Board Memberno datano datano data

5.1yrs

Average Tenure

62yo

Average Age

Experienced Board: PRQR's board of directors are considered experienced (5.1 years average tenure).